glp-1 eating disorder Use and misuse of receptor agonists were common in people with disorders, interim results of an ongoing cross-sectional study suggested. Among over 400 people with eating disorders in an interim Implications of GLP-1 medications for

Whether that justifies an extra $100 to $150 per month depends on your goals, your budget, and your individual response to medication

When left untreated, fatty liver disease can lead to inflammation, scarring, and even cirrhosis

In August 2025, the FDA approved semaglutide to treat MASH with moderate to advanced liver fibrosis

GLP-1 agonists are known to enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety

Working closely with a gynecologist or reproductive endocrinologist can help address fertility concerns

TRICARE policy has never approved coverage for GLP-1 drugs simply to lose weight or for cosmetic purposes